	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S111-PMC2290997	PMC2290997	4/2008	S111-PMC2290997	['in the context of INADEQUATE sunlight or Vitamin D insufficiency, SOME scientists WORRY that the EMPHASIS on preventing skin cancers tends to obscure the much larger mortality BURDEN posed by more Life-threatening cancers such as Lung, Colon, and Breast cancers.']	[('IMPORTANT_CONSIDERATION', 18), ('INCOMPLETE_EVIDENCE', 66), ('IMPORTANT_CONSIDERATION', 82), ('IMPORTANT_CONSIDERATION', 97), ('IMPORTANT_CONSIDERATION', 176)]	5	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('UBERON_0000104', 'life cycle', 197, 'life'), ('UBERON_0002048', 'lung', 230, 'lung'), ('UBERON_0001155', 'colon', 236, 'colon'), ('UBERON_0000310', 'breast', 247, 'breast')]
S128-PMC2873552	PMC2873552	4/2010	S128-PMC2873552	"[""caption (table-wrap): table 2\n\nfunctions and diseases related to both ceu and yri Signaturesceuyri diabetes 1.70e-172.70e-20 Coronary Artery disease 3.78e-173.12e-13 Genetic disorder 1.09e-144.53e-14 Cardiovascular disease 1.34e-144.78e-11 non-Insulin-dependent diabetes mellitus 1.03e-128.66e-15 Endocrine System disorder 1.91e-121.25e-18 hypertension 2.13e-122.83e-11 Neurological disorder 2.49e-123.27e-12 crohn's disease 7.59e-127.25e-09 bipolar affective disease 3.50e-115.24e-09 Metabolic disorder 5.66e-119.83e-16 inflammatory disorder 2.56e-091.08e-08 Digestive System disorder 2.66e-091.31e-07 Skeletal and muscular disorder 1.49e-081.58e-08 progressive motor neuropathy 2.53e-085.59e-12 Autoimmune disease 7.28e-081.09e-12 immunological disorder 2.46e-073.66e-13 rheumatoid arthritis 3.78e-072.54e-07 shape change of Epithelial Cells 8.86e-07 alzheimer's disease 3.60e-062.27e-07 parkinson's disease 7.24e-065.29e-06 shape change of Dermal Cells 9.33e-06 Insulin-dependent diabetes mellitus 3.76e-15 neuropathy 5.38e-12 amyotrophic lateral sclerosis 1.36e-09 arthritis 1.44e-07\n\nVitamin D HYPOTHESIS\nan INTERESTING HYPOTHESIS HAS BEEN PROPOSED by mcgrace [28] claiming that low Prenatal Vitamin D increases the risk of a wide range of diseases such as multiple sclerosis, diabetes, schizophrenia, Prostate cancer, Breast cancer and Colorectal cancer because of its versatile function in normal development.""]"	[('INCOMPLETE_EVIDENCE', 1099), ('ANOMALY_CURIOUS_FINDING', 1113), ('INCOMPLETE_EVIDENCE', 1125), ('INCOMPLETE_EVIDENCE', 1136), ('INCOMPLETE_EVIDENCE', 1145)]	5	[('GO_0036367', 'light adaption', 82, 'signaturesCEUYRI'), ('UBERON_0001621', 'coronary artery', 125, 'Coronary artery'), ('SO_0000704', 'gene', 166, 'Genetic'), ('UBERON_0004535', 'cardiovascular system', 200, 'Cardiovascular'), ('PR_000045358', 'insulin family protein', 244, 'insulin'), ('UBERON_0000949', 'endocrine system', 297, 'Endocrine system'), ('UBERON_0001016', 'nervous system', 370, 'Neurological'), ('GO_0008152', 'metabolic process', 485, 'Metabolic'), ('UBERON_0004854', 'gastrointestinal system mesentery', 560, 'Digestive system'), ('UBERON_0004288', 'skeleton', 603, 'Skeletal'), ('UBERON_0005445', 'segment of pes', 697, 'Autoimmune'), ('CL_0000066', 'epithelial cell', 827, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 827, 'epithelial'), ('CL_0000346', 'hair follicle dermal papilla cell', 943, 'dermal cells'), ('PR_000045358', 'insulin family protein', 965, 'Insulin'), ('CHEBI_28384', 'vitamin K', 1089, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1188, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1197, 'vitamin D'), ('UBERON_0002367', 'prostate gland', 1307, 'prostate'), ('UBERON_0000310', 'breast', 1324, 'breast'), ('UBERON_0012652', 'colorectum', 1342, 'colorectal')]
S98-PMC3034879	PMC3034879	12/2010	S98-PMC3034879	['caption (table-wrap): table\xa01\n\nbackground characteristics and changes in them from baseline value given as mean (sd)low dhigh dindependent samples t -test n 4443age, months14.9 (0.5)14.8 (0.5)0.336males, %58550.842aanthropometric and growth variables \xa0weight, kg10.8 (1.3)10.8 (1.3)0.997\xa0relative weight−1.2 (8.1)0.2 (6.7)0.382\xa0∆weight, kg7.1 (1.1)7.2 (1.0)0.624\xa0weight velocity, g/month475 (72)488 (67)0.446\xa0height, cm79.0 (2.8)78.4 (3.5)0.386\xa0height z-score0.25 (1.0)0.03 (1.2)0.378\xa0∆height, cm27.9 (2.0)27.7 (2.9)0.732\xa0height velocity, cm/month1.88 (0.12)1.87 (0.19)0.951 history of Breast feeding and dietary intakes \xa0duration of exclusive breastfeeding, months4.2 (1.9)4.3 (2.0)0.755\xa0currently Breastfed, n (%)11 (26.8)7 (16.6)0.196a\xa0energy intake, kcal/day920 (220)930 (180)0.770\xa0fat intake, g/day28.6 (7.9)28.0 (6.9)0.698\xa0protein Intake, g/day43 (13)42 (10)0.481\xa0Calcium intake, mg/day820 (320)840 (260)0.863\xa0total intake of Vitamin D, μg/day12.4 (3.1)12.2 (2.9)0.782 motor and language skills \xa0age when learnt to crawl, months8.0 (1.8)8.2 (1.8)0.690\xa0age when Learnt to stand, months8.4 (1.7)8.5 (1.6)0.668\xa0age when learnt to walk with support, months8.8 (1.6)10.1 (1.5)0.001\xa0age when Learnt to walk without support, months11.9 (1.6)12.1 (1.5)0.458\xa0number of words in use5.7 (6.2)6.8 (7.7)0.490\napearson chi square\nDESPITE lower Vitamin D concentration during Pregnancy and at Birth in low d than in high d (means 35.7 vs. 54.2\xa0nmol/l, and in the Cord 40.5 and 59.3\xa0nmol/l, independent samples t -test; p \u2009<\u20090.001, respectively), the 25-Ohd concentrations in the two groups at 14\xa0months were SIMILAR (63 vs. 66\xa0nmol/l, p \u2009=\u20090.58).']	[('ANOMALY_CURIOUS_FINDING', 1322), ('SUPERFICIAL_RELATIONSHIP', 1599)]	2	[('UBERON_0000310', 'breast', 586, 'breast'), ('GO_0007567', 'parturition', 699, 'breastfed'), ('GO_0007631', 'feeding behavior', 837, 'intake'), ('CHEBI_31341', 'calcium dihydroxide', 870, 'Calcium'), ('CHEBI_27300', 'vitamin D', 932, 'vitamin D'), ('GO_0007612', 'learning', 1067, 'learnt'), ('GO_0007612', 'learning', 1192, 'learnt'), ('CHEBI_27300', 'vitamin D', 1336, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1367, 'pregnancy'), ('GO_0007567', 'parturition', 1384, 'birth'), ('UBERON_0002240', 'spinal cord', 1454, 'cord'), ('CHEBI_72765', 'verruculogen', 1541, '25-OHD')]
S143-PMC3257641	PMC3257641	3/2010	S143-PMC3257641	['in Adult ecological and observational studies there is considerable EVIDENCE that Vitamin D status MAY BE RELATED to risk or prognosis of a number of cancers, including of the Prostate [121] and Breast [122].']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 99), ('SUPERFICIAL_RELATIONSHIP', 106)]	3	[('UBERON_0007023', 'adult organism', 3, 'adult'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0002367', 'prostate gland', 176, 'prostate'), ('UBERON_0000310', 'breast', 195, 'breast')]
S0-PMC3271033	PMC3271033	1/2012	S0-PMC3271033	['EFFECTS of ethnicity and Vitamin D supplementation on Vitamin D status and changes in bone Mineral content in infants\n\nabstract\n\nabstract\n\nbackground\nTO EVALUATE the EFFECTS on Serum 25(Oh)D and Bone mineralization of supplementation of Breast-Fed hispanic and non-hispanic caucasian infants with Vitamin D in infants in houston, texas.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 150), ('SUPERFICIAL_RELATIONSHIP', 166)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_46662', 'mineral', 91, 'mineral'), ('UBERON_0001977', 'blood serum', 177, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 186, 'OH)D'), ('GO_0007567', 'parturition', 195, 'bone'), ('UBERON_0000310', 'breast', 237, 'breast'), ('GO_0007631', 'feeding behavior', 244, 'fed'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D')]
S10-PMC3271033	PMC3271033	1/2012	S10-PMC3271033	['ALTHOUGH the dose of 400 iu daily is used for both Breast-Fed and formula-Fed babies, Vitamin D-deficient rickets is extremely rare in formula-Fed infants primarily due to the mandatory addition of Vitamin D to infant formulas in the united states.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('GO_0007567', 'parturition', 51, 'breast-'), ('UBERON_0000310', 'breast', 51, 'breast'), ('GO_0007631', 'feeding behavior', 58, 'fed'), ('GO_0007631', 'feeding behavior', 74, 'fed'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007631', 'feeding behavior', 143, 'fed'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]
S17-PMC3271033	PMC3271033	1/2012	S17-PMC3271033	"['THIS STUDY was CONDUCTED TO EVALUATE early Life bone Mineral content (bmc) and the EFFECTS of three months of Vitamin D supplementation in Breast-Fed hispanic and non-hispanic caucasian (henceforth, ""caucasian"") infants on Vitamin D levels.']"	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('SUPERFICIAL_RELATIONSHIP', 83)]	4	[('UBERON_0000104', 'life cycle', 43, 'life'), ('CHEBI_46662', 'mineral', 53, 'mineral'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('UBERON_0000310', 'breast', 139, 'breast'), ('GO_0007631', 'feeding behavior', 146, 'fed'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D')]
S132-PMC3271033	PMC3271033	1/2012	S132-PMC3271033	['HOWEVER, it is LIKELY that by three months of age, Vitamin D has a KEY ROLE in calcium absorption, especially in Breast-Fed infants with a relatively low Calcium Intake COMPARED TO formula-Fed infants.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 15), ('IMPORTANT_CONSIDERATION', 67), ('SUPERFICIAL_RELATIONSHIP', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169)]	5	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007567', 'parturition', 113, 'breast'), ('UBERON_0000310', 'breast', 113, 'breast'), ('GO_0007631', 'feeding behavior', 120, 'fed'), ('CHEBI_22313', 'alkaline earth metal atom', 154, 'calcium'), ('GO_0007631', 'feeding behavior', 162, 'intake'), ('GO_0007631', 'feeding behavior', 189, 'fed')]
S134-PMC3271033	PMC3271033	1/2012	S134-PMC3271033	['greer et al [16] FOUND an increase in 25(Oh)D from 24 to 39 ng/ml at three months of age with the provision of 400 iu/day of Vitamin D to Breast-Fed infants.']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 38, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007567', 'parturition', 138, 'breast'), ('UBERON_0000310', 'breast', 138, 'breast'), ('GO_0007631', 'feeding behavior', 145, 'fed')]
S159-PMC3271033	PMC3271033	1/2012	S159-PMC3271033	['OUR FINDINGS SUPPORT current GUIDELINES to begin Vitamin D supplementation of 400 iu/day to all Breast-Fed infants in the first week of Life and to FURTHER ENCOURAGE the provision of adequate Vitamin D to Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 29), ('FUTURE_WORK', 148), ('FUTURE_WORK', 156)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007567', 'parturition', 96, 'breast'), ('UBERON_0000310', 'breast', 96, 'breast'), ('GO_0007631', 'feeding behavior', 103, 'fed'), ('UBERON_0000104', 'life cycle', 136, 'life'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('GO_0007565', 'female pregnancy', 205, 'pregnant')]
S51-PMC3272870	PMC3272870	12/2011	S51-PMC3272870	['Vitamin D is LIKELY SAFE during Pregnancy and Breast feeding when taken by mouth in RECOMMENDED amounts, that is 10 mcg (400 usp units) of Vitamin D daily in normal Pregnancy.']	[('PROBABLE_UNDERSTANDING', 13), ('IMPORTANT_CONSIDERATION', 20), ('FUTURE_WORK', 84)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 32, 'pregnancy'), ('UBERON_0000310', 'breast', 46, 'breast'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy')]
S76-PMC3296991	PMC3296991	2/2012	S76-PMC3296991	['season, maternal age, race, pre-Gestational bmi, Vitamin D intake, and Vitamin D status and infant age at the time of the scan, Gestational age at Birth, Feeding pattern (Breast Fed, Formula Fed, or mixed) and Vitamin D status did NOT remain in the final predictive models.']	[('ANOMALY_CURIOUS_FINDING', 231)]	1	[('GO_0007565', 'female pregnancy', 32, 'gestational'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 128, 'gestational'), ('GO_0007567', 'parturition', 147, 'birth'), ('GO_0007631', 'feeding behavior', 154, 'feeding'), ('GO_0007567', 'parturition', 171, 'breast fed'), ('UBERON_0000310', 'breast', 171, 'breast'), ('GO_0009407', 'toxin catabolic process', 183, 'formula fed'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D')]
S18-PMC3313761	PMC3313761	3/2012	S18-PMC3313761	['hypocalcemia HAS also BEEN shown to occur in exclusively Breast Fed babies not exposed to sunlight and in infants whose mothers are deficient in Vitamin D.[1] symptoms of hypocalcemia in children include lethargy, recurrent Respiratory Tract infections, focal clonic seizures, jitteriness, carpopedal spasm and RARELY stridor DUE TO laryngospasm.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 311), ('PROBLEM_COMPLICATION', 326)]	3	[('GO_0007567', 'parturition', 57, 'breast'), ('UBERON_0000310', 'breast', 57, 'breast'), ('GO_0007631', 'feeding behavior', 64, 'fed'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('UBERON_0000065', 'respiratory tract', 224, 'respiratory tract')]
S78-PMC3347028	PMC3347028	3/2012	S78-PMC3347028	['these in vitro FINDINGS HELP to EXPLAIN the significant ASSOCIATION between Vitamin D deficiency and Autoimmune diseases, such as systemic lupus erythematosus [25], multiple sclerosis [26,27,28,29,30,31,32,33,34,35], rheumatoid arthritis [31,36,37], diabetes—both types 1 [31,38,39,40,41,42] and 2 [43,44,45], and certain cancers, such as Colon [46,47,48,49], Breast [50,51,52,53,54,55], and Prostate [55,56,57,58,59].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 24), ('PROBABLE_UNDERSTANDING', 32), ('SUPERFICIAL_RELATIONSHIP', 56)]	4	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 101, 'autoimmune'), ('UBERON_0001155', 'colon', 339, 'colon'), ('UBERON_0000310', 'breast', 360, 'breast'), ('UBERON_0002367', 'prostate gland', 392, 'prostate')]
S102-PMC3356951	PMC3356951	4/2012	S102-PMC3356951	['there is SOME EVIDENCE LINKING higher Vitamin D intake to a lower RISK for Breast cancer.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 23), ('IMPORTANT_CONSIDERATION', 66)]	3	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0000310', 'breast', 75, 'breast')]
S76-PMC3366289	PMC3366289	7/2011	S76-PMC3366289	['Serum Retinol <1.05\xa0μmol/l and Breast Milk Retinol ≤1.05\xa0μmol/l or ≤28\xa0μmol/kg Milk fat (≤8\xa0μg/g milk fat) were considered INDICATIVE of low Vitamin A status and low Breast Milk Vitamin A content [18].']	[('PROBABLE_UNDERSTANDING', 123)]	1	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_26536', 'retinoic acid', 6, 'retinol'), ('UBERON_0000310', 'breast', 31, 'breast'), ('UBERON_0001913', 'milk', 38, 'milk'), ('CHEBI_26536', 'retinoic acid', 43, 'retinol'), ('UBERON_0001913', 'milk', 79, 'milk'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin A'), ('UBERON_0000310', 'breast', 166, 'breast'), ('UBERON_0001913', 'milk', 173, 'milk'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A')]
S141-PMC3366289	PMC3366289	7/2011	S141-PMC3366289	['the intake of Β-Carotene-rich vegetables, oils and fruits is RECOMMENDED in order to meet the Vitamin A REQUIREMENT for mothers and their Breast-Fed infants whose diet excludes the Consumption of meat, Liver and eggs [41].']	[('FUTURE_WORK', 61), ('IMPORTANT_CONSIDERATION', 104)]	2	[('CHEBI_28064', 'cyanidin 3-O-rutinoside', 14, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('GO_0007567', 'parturition', 138, 'breast'), ('UBERON_0000310', 'breast', 138, 'breast'), ('GO_0007631', 'feeding behavior', 145, 'fed'), ('GO_0007631', 'feeding behavior', 181, 'consumption'), ('UBERON_0002107', 'liver', 202, 'liver')]
S1-PMC3407995	PMC3407995	7/2012	S1-PMC3407995	['purpose: to highlight the POTENTIAL BENEFITS of maternal supplementation with Docosahexaenoic Acid (Dha) and other IMPORTANT complimentary Nutrients, including Vitamin D, Folic Acid and Iodine during Pregnancy and/or Breast feeding for Foetal and/or infant Brain Development and/or function.']	[('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 36), ('IMPORTANT_CONSIDERATION', 115)]	3	[('CHEBI_36003', 'decenoic acid', 78, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 100, 'DHA'), ('CHEBI_33284', 'nutrient', 139, 'nutrients'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_30751', 'formic acid', 171, 'folic acid'), ('CHEBI_24859', 'iodine atom', 186, 'iodine'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy'), ('UBERON_0000310', 'breast', 217, 'breast'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 236, 'foetal ...'), ('GO_0007420', 'brain development', 257, 'brain development'), ('UBERON_0000955', 'brain', 257, 'brain')]
S13-PMC3407995	PMC3407995	7/2012	S13-PMC3407995	['a review of current literature was UNDERTAKEN to summarize the POTENTIAL benefits of maternal supplementation with Dha, Vitamin D, Folic Acid and Iodine during Pregnancy and/or Breast feeding for Foetal and/or infant Brain Development and/or function.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('INCOMPLETE_EVIDENCE', 63)]	2	[('CHEBI_17874', 'dihydrozeatin', 115, 'DHA'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_30751', 'formic acid', 131, 'folic acid'), ('CHEBI_24859', 'iodine atom', 146, 'iodine'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('UBERON_0000310', 'breast', 177, 'breast'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 196, 'foetal ...'), ('GO_0007420', 'brain development', 217, 'brain development'), ('UBERON_0000955', 'brain', 217, 'brain')]
S435-PMC3407995	PMC3407995	7/2012	S435-PMC3407995	['their RECOMMENDATION was 37.5–50 μg 1500–2000 iu) per day in Pregnant and Lactating women with Vitamin D deficiency [172].table 1includes RECOMMENDATIONS from various health agencies and governments around the world.Nutrients-04-00799-t001_table 1\n\ncaption (table-wrap): table 1\n\nVitamin D intake RECOMMENDATIONS during Pregnancy and Lactation.agency/governmentrecommendationuk—for the elderly, Pregnant & Lactating women [173]dietary reference values 10 µg/day (400 iu/day)uk department of health 2007—for Pregnant and Lactating women [45]10 µg/day (400 iu/day)uk national institute of health and clinical excellence guideline review panel 2007 [45]all women SHOULD BE informed about the IMPORTANCE for their own and their baby’s health of maintaining adequate Vitamin D stores during Pregnancy and whilst Breast feeding and may choose to take 400 iu/day.canadian paediatric society [45]50 μg/day (2000 iu/day) throughout Pregnancyfederal department of health canada [45]5 μg/day (200 iu/day) for Pregnant and Breast-feeding womeneuropean commission [45]10 μg/day (400 iu/day) during Pregnancyworld health organisation 2004 [45]5 μg/day (200 iu/day) during Pregnancythe institute of medicine us 2010 [172,174]15 μg/day (600 iu/day) in Pregnant and Lactating womenus Endocrine task force on Vitamin D 2011 [174]37.5–50 μg/day (1500–2000 iu) in Pregnant and Lactating women with Vitamin D deficiency.']	[('FUTURE_WORK', 6), ('FUTURE_WORK', 138), ('FUTURE_WORK', 297), ('FUTURE_WORK', 660), ('IMPORTANT_CONSIDERATION', 689)]	5	[('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('GO_0007594', 'puparial adhesion', 74, 'lactating'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33284', 'nutrient', 216, 'nutrients'), ('CHEBI_28384', 'vitamin K', 280, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 320, 'pregnancy'), ('GO_0007595', 'lactation', 334, 'lactation'), ('GO_0007565', 'female pregnancy', 395, 'pregnant'), ('GO_0007594', 'puparial adhesion', 406, 'lactating'), ('GO_0007565', 'female pregnancy', 507, 'pregnant'), ('GO_0007594', 'puparial adhesion', 520, 'lactating'), ('CHEBI_27300', 'vitamin D', 762, 'vitamin D'), ('GO_0007565', 'female pregnancy', 786, 'pregnancy'), ('UBERON_0000310', 'breast', 807, 'breast'), ('GO_0007565', 'female pregnancy', 923, 'pregnancyFederal'), ('GO_0007565', 'female pregnancy', 998, 'pregnant'), ('UBERON_0000310', 'breast', 1011, 'breast'), ('GO_0014065', 'phosphatidylinositol 3-kinase signaling', 1085, 'pregnancyWorld'), ('GO_0036240', 'septal periplasm', 1158, 'pregnancyThe'), ('GO_0007565', 'female pregnancy', 1236, 'pregnant'), ('GO_0007594', 'puparial adhesion', 1249, 'lactating'), ('GO_0009790', 'embryo development', 1267, 'Endocrine'), ('UBERON_0005063', 'left ventricular compact myocardium', 1267, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 1291, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1291, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1344, 'pregnant'), ('GO_0007594', 'puparial adhesion', 1357, 'lactating'), ('CHEBI_27300', 'vitamin D', 1378, 'vitamin D')]
S127-PMC3465343	PMC3465343	10/2012	S127-PMC3465343	['Teratogenic EFFECTS of Vitamin A deficiency and excess both involve Skeletal Morphogenesis, and these abnormalities include hypoplastic Cranial Bones, defects of the Thyroid, Cricoid and Tracheal Cartilages as well as agenesis of the Neural Arch of Cervical Vertebrae 1 and ectopic bone in the dorsal regions of C1, malformation of the Sternal and Pelvic Regions[29].']	[('SUPERFICIAL_RELATIONSHIP', 12)]	1	[('CHEBI_73676', '3-deoxychenodeoxycholic acid', 0, 'Teratogenic'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin A'), ('GO_0001501', 'skeletal system development', 68, 'skeletal morphogenesis'), ('UBERON_0004288', 'skeleton', 68, 'skeletal'), ('UBERON_0004766', 'cranial bone', 136, 'cranial bones'), ('UBERON_0002046', 'thyroid gland', 166, 'thyroid'), ('UBERON_0001566', 'cricothyroid muscle', 175, 'cricoid'), ('UBERON_0000310', 'breast', 187, 'tracheal cartilages'), ('UBERON_0003861', 'neural arch', 234, 'neural arch'), ('UBERON_0002413', 'cervical vertebra', 249, 'cervical vertebrae'), ('UBERON_0003124', 'chorion', 312, 'C1'), ('UBERON_0001905', 'pineal body', 336, 'sternal ...'), ('UBERON_0002401', 'visceral pleura', 348, 'pelvic regions')]
S17-PMC3470091	PMC3470091	9/2012	S17-PMC3470091	['studies have INDICATED that during Pregnancy Vitamin D deficiency varies from 18% to 84%, which varies with the region under the study and type of clothing.2,3vitamin d deficiency among Breast-Fed children in the regions with heavy sunshine such as the middle east is high.3-5this hypovitaminosis which is DUE TO limited exposure to sun of mothers’ and their babies as well as low Vitamin D intake by mothers.']	[('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 306)]	2	[('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007567', 'parturition', 186, 'breast'), ('UBERON_0000310', 'breast', 186, 'breast'), ('GO_0007631', 'feeding behavior', 193, 'fed'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D')]
S74-PMC3613945	PMC3613945	2/2013	S74-PMC3613945	['ASSOCIATION between common Genetic variants of the Vitamin D Binding Protein Gene (gc) and various diseases.sample size ( n )diseasereferencecasescontrolscountryethnicitygc polymorphisms studiedfindings cancer Breast cancerabbas et al.16014022608germanycaucasianagc1f, gc1s, gc2genotype Gc2-2 was ASSOCIATED with decreased risk of Postmenopausal Breast cancer, [or\u2009=\u20090.72 (ci\u2009=\u20090.54–0.96, p \u2009=\u20090.04)], when compared to the most frequently observed genotype, gc1s-1s.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 297)]	2	[('SO_0000704', 'gene', 27, 'genetic'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 51, 'vitamin D binding protein'), ('SO_0000704', 'gene', 77, 'gene'), ('UBERON_0000310', 'breast', 210, 'Breast'), ('PR_000008010', 'glycerol kinase', 287, 'Gc2-2'), ('GO_0007595', 'lactation', 331, 'postmenopausal'), ('UBERON_0000310', 'breast', 346, 'breast')]
S210-PMC3613945	PMC3613945	2/2013	S210-PMC3613945	['Breast cancer\necological case-control studies INDICATE an inverse CORRELATION between Vitamin D status and Breast cancer RISK, HOWEVER, the RELATIONSHIP is LESS CLEAR in longitudinal studies150,151.']	[('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 66), ('IMPORTANT_CONSIDERATION', 121), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('ANOMALY_CURIOUS_FINDING', 127), ('SUPERFICIAL_RELATIONSHIP', 140), ('FULL_UNKNOWN', 156)]	7	[('UBERON_0000310', 'breast', 0, 'Breast'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('UBERON_0000310', 'breast', 107, 'breast')]
S211-PMC3613945	PMC3613945	2/2013	S211-PMC3613945	['MUCH work HAS BEEN done to elucidate a Vitamin D-RELATED mechanistic ROLE in Breast cancer.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 49), ('SUPERFICIAL_RELATIONSHIP', 69)]	4	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('UBERON_0000310', 'breast', 77, 'breast')]
S214-PMC3613945	PMC3613945	2/2013	S214-PMC3613945	['ALTERNATIVELY, the active Metabolite of Vitamin D, Calcitriol, HAS BEEN SHOWN to inhibit Cell Proliferation and Differentiation and promote Apoptosis of Breast tumor Tissue155–158.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 63)]	2	[('CHEBI_39382', 'flufenoxuron', 26, 'metabolite'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 51, 'calcitriol'), ('GO_0030154', 'cell differentiation', 89, 'cell proliferation ... differentiation'), ('GO_0006915', 'apoptotic process', 140, 'apoptosis'), ('UBERON_0000310', 'breast', 153, 'breast'), ('UBERON_0003605', 'eye skin gland', 166, 'tissue155')]
S218-PMC3613945	PMC3613945	2/2013	S218-PMC3613945	['both THESE STUDIES ARGUE AGAINST a ROLE for gc-maf or Vitamin D in Breast cancer pathogenesis.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 35)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('UBERON_0000310', 'breast', 67, 'breast')]
S2-PMC3629265	PMC3629265	4/2013	S2-PMC3629265	['CURRENTLY, Vitamin D supplementation is RECOMMENDED in canada for Breast Fed infants.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 40)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007567', 'parturition', 66, 'breast'), ('UBERON_0000310', 'breast', 66, 'breast'), ('GO_0007631', 'feeding behavior', 73, 'fed')]
S58-PMC3629265	PMC3629265	4/2013	S58-PMC3629265	['there HAVE BEEN several recent REPORTS of SEVERE Vitamin D deficiency presenting with hypocalcaemic seizures in Breast Fed infants.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 31), ('IMPORTANT_CONSIDERATION', 42)]	3	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007567', 'parturition', 112, 'breast fed'), ('UBERON_0000310', 'breast', 112, 'breast')]
S64-PMC3629265	PMC3629265	4/2013	S64-PMC3629265	['the current statement put forth by the canadian paediatric society, dieticians of canada, and health canada on nutrition for term infants RECOMMENDS supplementing with 400 iu/day of Vitamin D only for Breast Fed infants (22).']	[('FUTURE_WORK', 138)]	1	[('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('GO_0007567', 'parturition', 201, 'breast'), ('UBERON_0000310', 'breast', 201, 'breast'), ('GO_0007631', 'feeding behavior', 208, 'fed')]
S67-PMC3629265	PMC3629265	4/2013	S67-PMC3629265	['the canadian paediatric society statement does not clearly differentiate Breast-Fed vs. formula-Fed infants but does SUGGEST that infant formulas SHOULD BE an adequate source of Vitamin D as long as the infant consumes “adequate quantity” (23).']	[('INCOMPLETE_EVIDENCE', 117), ('FUTURE_WORK', 146)]	2	[('GO_0007567', 'parturition', 73, 'breast-'), ('UBERON_0000310', 'breast', 73, 'breast'), ('GO_0007631', 'feeding behavior', 80, 'fed'), ('GO_0007631', 'feeding behavior', 96, 'fed'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S71-PMC3629265	PMC3629265	4/2013	S71-PMC3629265	['a RECENT telephone survey of mothers of full-term infants in montreal IDENTIFIED that infants Consuming mixed Feedings (Breast and formula) and those exclusively formula-Fed were at high risk of not meeting recommended Vitamin D intake in the first 6 months of Life (25).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 70)]	2	[('GO_0007631', 'feeding behavior', 94, 'consuming'), ('GO_0007631', 'feeding behavior', 110, 'feedings'), ('UBERON_0000310', 'breast', 120, 'breast'), ('GO_0007631', 'feeding behavior', 170, 'fed'), ('CHEBI_27300', 'vitamin D', 219, 'vitamin D'), ('UBERON_0000104', 'life cycle', 261, 'life')]
S136-PMC3659910	PMC3659910	1/2013	S136-PMC3659910	['a sufficient supply of Vitamin D to the Breast Fed infant is achieved ONLY by increasing the maternal supplementation up to 2000 iu/day.']	[('INCOMPLETE_EVIDENCE', 70)]	1	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007567', 'parturition', 40, 'breast fed'), ('UBERON_0000310', 'breast', 40, 'breast')]
S185-PMC3659910	PMC3659910	1/2013	S185-PMC3659910	['HOWEVER, getting 25(Oh) D levels consistently above 75 nmol/l (30 ng/ml) MAY REQUIRE AT LEAST 1500-2000 iu/day of Vitamin D. if a mother is Vitamin D deficient, Breast Milk is not a good source of Vitamin D, so infants need to be given Vitamin D supplementation until they are weaned.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 73), ('FUTURE_WORK', 77), ('PROBABLE_UNDERSTANDING', 85)]	4	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 24, 'D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('UBERON_0000310', 'breast', 161, 'breast'), ('UBERON_0001913', 'milk', 168, 'milk'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
S187-PMC3659910	PMC3659910	1/2013	S187-PMC3659910	['it was RECENTLY SHOWN that a maternal supplementation of 2100 iu Vitamin D/day was NEEDED, when administered during the period of Lactation, in order to observe an increase in Serum levels of 25(Oh) D in the Breast-Fed infants comparable to that observed in children given 400 iu/day.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 83)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007595', 'lactation', 130, 'lactation'), ('UBERON_0001977', 'blood serum', 176, 'serum'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH) D'), ('PR_000010220', 'mannose-binding protein C', 194, '('), ('PR_000006444', 'diacylglycerol kinase delta', 199, 'D'), ('GO_0007567', 'parturition', 208, 'breast'), ('UBERON_0000310', 'breast', 208, 'breast'), ('GO_0007631', 'feeding behavior', 215, 'fed')]
S31-PMC3668200	PMC3668200	5/2013	S31-PMC3668200	['the american academy of pediatrics (aap) PREVIOUSLY RECOMMENDED a daily Vitamin D intake of 200 iu for exclusively Breast-Fed infants.']	[('INCOMPLETE_EVIDENCE', 41), ('FUTURE_WORK', 52)]	2	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007567', 'parturition', 115, 'breast'), ('UBERON_0000310', 'breast', 115, 'breast'), ('GO_0007631', 'feeding behavior', 122, 'fed')]
S33-PMC3668200	PMC3668200	5/2013	S33-PMC3668200	['RECENTLY, aap RECOMMENDATION of 400 iu/day for Vitamin D supplementation was DOCUMENTED to maintain a 25(Oh)D Serum concentration higher than 50 nmol/l in exclusively Breast-Fed infants15).']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 14), ('INCOMPLETE_EVIDENCE', 77)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 102, '25(OH)D'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('GO_0007567', 'parturition', 167, 'breast'), ('UBERON_0000310', 'breast', 167, 'breast'), ('GO_0007631', 'feeding behavior', 174, 'fed')]
S74-PMC3691177	PMC3691177	6/2013	S74-PMC3691177	['as PREVIOUSLY reported[19], median Cord 25(Oh)D levels at Delivery were significantly higher in supplemented children COMPARED TO the control group [control 17 nmol/l (interquartile range (iqr) 14–22); daily dose 26 nmol/l (iqr 17–45); p<0.001; bolus dose 25 nmol/l (iqr 18–34); p<0.001)].10.1371/journal.pone.0066627.g001\n\ncaption (fig): figure 1\nrecruitment and follow up of study participants.10.1371/journal.pone.0066627.t001\n\ncaption (table-wrap): table 1\ncharacteristics of study participants followed up at age three years.controldaily Vitamin dbolus vitamin dcombined Vitamin D(n\u200a=\u200a50)(n\u200a=\u200a56)(n\u200a=\u200a52)(n\u200a=\u200a108)baseline maternal 25(Oh)D <25 nmol/l, n/n (%)24/50 (48)25/56 (45)22/52 (42)47/108 (44)male sex, n/n (%)27/50 (54)32/56 (57)26/52 (50)58/108 (55)Birth weight (g), mean (sd)3268 (585)3321 (525)3290 (467)3307 (497)ethnicity, n (%)asian12 (24)15 (27)13 (25)28 (26)middle eastern13 (26)14 (25)14 (26)28 (26)black12 (24)14 (25)13 (25)27 (25)white13 (26)13 (23)12 (24)25 (23)ga at Delivery (weeks), mean (sd)40 (1)39 (2)40 (1)39 (2)nulliparous mother, n/n (%)23/50 (46)20/56 (36)21/52 (40)41/108 (38)Vaginal Delivery, n/n (%)29/50 (58)35/56 (63)28/52 (54)63/108 (58)maternal smoking during Pregnancy, n/n (%)2/48 (4)3/55 (5)0/46 (0)3/101 (3)presence of household smokers, n/n (%)16/48 (33)15/55 (27)17/46 (37)32/101 (32)number of children in household, mean (sd)2 (1)2 (1)2 (1)2 (1)age mother left full time education, mean (sd)20 (3)20 (4)21 (4)21 (4)child in nursery, n/n (%)27/48 (56)36/55 (65)20/45 (44)57/101 (56)Cat or Dog in household, n/n (%)4/48 (8)5/54 (9)4/46 (9)9/100 (9)maternal fitzpatrick skin score grade 3–6, n/n (%)28/44 (64)33/49 (67)28/43 (65)61/92 (66)maternal regular vitamin intake at three years, n/n (%)9/46 (20)16/53 (30)16/45 (36)32/98 (33)at least one parent with allergic disease, n/n (%)23/45 (51)35/53 (66)21/45 (47)56/98 (57)exclusively Breast-Fed for 4 months, n/n (%)22/48 (46)20/54 (37)23/44 (52)43/98 (44)any child vitamin supplementation, n/n (%)30/48 (63)34/55 (62)30/46 (65)64/101 (63)completed immunizations to date, n/n (%)48/49 (98)54/55 (98)43/47 (91)97/102 (95)age at time of assessment (months), median (iqr)37.9 (36.9, 39.9)37.1 (36.5, 38.8)37.4 (36.5, 39.5)37.3 (36.5, 39.0)child fitzpatrick skin score grade 3–6, n (%)29/42 (69)34/48 (71)29/43 (67)63/91 (69)child bmi z score age 3, mean (sd)0.51 (1.48)0.35 (1.15)0.62 (1.15)0.47 (1.15)child outdoors >1 hour/day, n/n (%)32/48 (67)34/53 (64)33/45 (73)67/98 (68)child tv/computer >2 hours/day, n/n (%)24/48 (50)18/53 (34)17/45 (38)35/98 (36)child 25(Oh)D (nmol/l) age 3, median (iqr)42 (27, 68)35 (21, 66)42 (30, 93)41 (26, 72)\ndata shown are for all participants analysed.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118)]	2	[('UBERON_0002240', 'spinal cord', 35, 'cord'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 40, '25(OH ... D'), ('GO_0007567', 'parturition', 58, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 543, 'vitamin'), ('CHEBI_27300', 'vitamin D', 576, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 636, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 636, '25(OH ... D'), ('GO_0007567', 'parturition', 762, 'Birth'), ('GO_0007567', 'parturition', 992, 'delivery'), ('GO_0007567', 'parturition', 1111, 'Vaginal'), ('UBERON_0000970', 'eye', 1111, 'Vaginal'), ('GO_0007567', 'parturition', 1119, 'delivery'), ('GO_0007565', 'female pregnancy', 1201, 'pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 1529, 'Cat'), ('NCBITaxon_33208', 'Metazoa', 1536, 'dog'), ('GO_0007567', 'parturition', 1880, 'breast'), ('UBERON_0000310', 'breast', 1880, 'breast'), ('GO_0007631', 'feeding behavior', 1887, 'fed'), ('CHEBI_71657', 'versiconol acetate', 2555, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 2558, 'OH)D')]
S10-PMC3702245	PMC3702245	6/2013	S10-PMC3702245	['a second hydroxylation takes place in the Kidney, which converts 25(Oh)D to the most biologically active Metabolite, 1,25-Dihydroxyvitamin D, the major classical physiologic function of which is to increase calcium and Phosphorus absorption from the Gut in order to maintain Calcium Homeostasis and promote mineralization of Osteoid bone.9\nalthough the Renal 1-alpha hydroxylase (Cytochrome P450 [Cyp]27B1) enzyme is a MAJOR DETERMINANT of Synthesis of 1,25-Dihydroxyvitamin D, IT IS KNOWN that Cyp27B1 is Expressed in Nonrenal Tissues to produce 1,25 Dihydroxyvitamin D.6,19in addition, Vitamin D receptors are also Expressed in a variety of Organs, Tissues, and cells (seefigure 1).20the 1,25-Dihydroxyvitamin D locally produced in Extrarenal Tissues, such as immune cells, Pancreatic Beta Cells, the Intestine, Prostate, Breast, and other Organs, Controls multiple Vitamin D-responsive Genes, and THUS plays an important physiologic ROLE in Cardiovascular health,21,22the Adaptive and Innate Immune Responses,23,24insulin secretion,25,26regulation of Cell Proliferation, Differentiation, and Apoptosis, and inhibition of Angiogenesis.27\n\nVitamin D Homeostasis and functions during Pregnancy\nthe classical function of Vitamin D is to maintain calcium Homeostasis.']	[('IMPORTANT_CONSIDERATION', 419), ('SUPERFICIAL_RELATIONSHIP', 425), ('INCOMPLETE_EVIDENCE', 478), ('PROBABLE_UNDERSTANDING', 900), ('SUPERFICIAL_RELATIONSHIP', 936)]	5	[('UBERON_0002113', 'kidney', 42, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('CHEBI_39382', 'flufenoxuron', 105, 'metabolite'), ('CHEBI_67472', '15-epi-lupulin B', 117, '1,25-dihydroxyvitamin D'), ('CHEBI_35885', 'secondary phosphine', 219, 'phosphorus'), ('UBERON_0001555', 'digestive tract', 250, 'gut'), ('GO_0055073', 'cadmium ion homeostasis', 275, 'calcium homeostasis'), ('UBERON_0008883', 'osteoid', 325, 'osteoid'), ('UBERON_0002113', 'kidney', 353, 'renal'), ('CHEBI_4056', 'cytochrome', 380, 'cytochrome'), ('PR_000006100', 'aromatase', 380, 'cytochrome P450'), ('PR_000006138', 'cytochrome P450 4F11', 397, 'CYP ... 27B1'), ('GO_0009057', 'macromolecule catabolic process', 440, 'synthesis'), ('CHEBI_67472', '15-epi-lupulin B', 453, '1,25-dihydroxyvitamin D'), ('PR_000006101', 'cytochrome P450 1A1', 495, 'CYP27B1'), ('GO_0010467', 'gene expression', 506, 'expressed'), ('UBERON_0002481', 'bone tissue', 519, 'nonrenal tissues'), ('CHEBI_67469', '15-hydroxyajubractin C', 547, '1,25 dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 588, 'vitamin D'), ('GO_0010467', 'gene expression', 617, 'expressed'), ('UBERON_0000062', 'organ', 643, 'organs'), ('UBERON_0000479', 'tissue', 651, 'tissues'), ('CHEBI_67472', '15-epi-lupulin B', 690, '1,25-dihydroxyvitamin D'), ('UBERON_0005292', 'extraembryonic tissue', 734, 'extrarenal tissues'), ('CL_0000169', 'type B pancreatic cell', 776, 'pancreatic beta cells'), ('UBERON_0001264', 'pancreas', 776, 'pancreatic'), ('UBERON_0000160', 'intestine', 803, 'intestine'), ('UBERON_0002367', 'prostate gland', 814, 'prostate'), ('UBERON_0000310', 'breast', 824, 'breast'), ('UBERON_0000062', 'organ', 842, 'organs'), ('GO_0065007', 'biological regulation', 850, 'controls'), ('CHEBI_27300', 'vitamin D', 868, 'vitamin D'), ('SO_0000704', 'gene', 889, 'genes'), ('UBERON_0004535', 'cardiovascular system', 944, 'cardiovascular'), ('GO_0051886', 'negative regulation of timing of anagen', 975, 'adaptive ...'), ('GO_0044419', 'biological process involved in interspecies interaction between organisms', 988, 'innate immune responses'), ('UBERON_0002405', 'immune system', 995, 'immune'), ('GO_0030154', 'cell differentiation', 1054, 'cell proliferation ... differentiation'), ('GO_0006915', 'apoptotic process', 1095, 'apoptosis'), ('GO_0001525', 'angiogenesis', 1124, 'angiogenesis'), ('CHEBI_28384', 'vitamin K', 1141, 'Vitamin D'), ('GO_0042592', 'homeostatic process', 1151, 'homeostasis'), ('GO_0007565', 'female pregnancy', 1184, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1220, 'vitamin D'), ('GO_0042592', 'homeostatic process', 1253, 'homeostasis')]
S1-PMC3717170	PMC3717170	5/2013	S1-PMC3717170	['the POSSIBILITY of Extraskeletal EFFECTS of Vitamin D was FIRST NOTED with the discovery of the Vitamin D Receptor (vdr) in Tissues and cells that are not involved in maintaining Mineral Homeostasis and bone health, including skin, Placenta, Pancreas, Breast, Prostate and Colon cancer cells, and Activated T Cells.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 58), ('ANOMALY_CURIOUS_FINDING', 64)]	4	[('UBERON_0001431', 'distal carpal bone 2', 19, 'extraskeletal'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 96, 'vitamin D receptor'), ('UBERON_0000479', 'tissue', 124, 'tissues'), ('CHEBI_46662', 'mineral', 179, 'mineral'), ('GO_0055085', 'transmembrane transport', 179, 'mineral homeostasis'), ('UBERON_0001987', 'placenta', 232, 'placenta'), ('UBERON_0001264', 'pancreas', 242, 'pancreas'), ('UBERON_0000310', 'breast', 252, 'breast'), ('UBERON_0002367', 'prostate gland', 260, 'prostate'), ('UBERON_0001155', 'colon', 273, 'colon'), ('CL_0002129', 'regular atrial cardiac myocyte', 297, 'activated T cells')]
S10-PMC3717170	PMC3717170	5/2013	S10-PMC3717170	['WHILE it was LONG HELD that Vitamin D ACTED only at the Intestine, Kidney, and Skeleton, and that its function was LIMITED to calcium Homeostasis, the POSSIBILITY of Extraskeletal EFFECTS HAS BEEN CONSIDERED for decades AS a result of the discovery of the vdr in Tissues that have no involvement in Calcium Homeostasis (e.g., skin, Placenta, Pancreas, Breast, Prostate and Colon cancer cells, and Activated T Cells).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 18), ('SUPERFICIAL_RELATIONSHIP', 38), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 151), ('SUPERFICIAL_RELATIONSHIP', 180), ('INCOMPLETE_EVIDENCE', 188), ('INCOMPLETE_EVIDENCE', 197), ('PROBABLE_UNDERSTANDING', 220)]	10	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('UBERON_0000160', 'intestine', 56, 'intestine'), ('UBERON_0002113', 'kidney', 67, 'kidney'), ('UBERON_0004288', 'skeleton', 79, 'skeleton'), ('GO_0042592', 'homeostatic process', 134, 'homeostasis'), ('UBERON_0001431', 'distal carpal bone 2', 166, 'extraskeletal'), ('UBERON_0000479', 'tissue', 263, 'tissues'), ('GO_0055073', 'cadmium ion homeostasis', 299, 'calcium homeostasis'), ('UBERON_0001987', 'placenta', 332, 'placenta'), ('UBERON_0001264', 'pancreas', 342, 'pancreas'), ('UBERON_0000310', 'breast', 352, 'breast'), ('UBERON_0002367', 'prostate gland', 360, 'prostate'), ('UBERON_0001155', 'colon', 373, 'colon'), ('CL_0002129', 'regular atrial cardiac myocyte', 397, 'activated T cells')]
S18-PMC3717170	PMC3717170	5/2013	S18-PMC3717170	['IN ORDER TO DETERMINE mechanisms INVOLVED in inhibition of Breast tumor growth, christakos’ lab SHOWED that C/Ebpα, a transcription factor that HAS BEEN SHOWN to play a CRITICAL ROLE in growth arrest of other cell types, is induced by 1,25(Oh)2D3In mcf-7 Human Breast cancer cells.2c/Ebpα was found to induce transcription of the Vitamin D receptor in mcf-7 cells.2since the levels of the vdr CORRELATE with the antiproliferative effects of 1,25(Oh)2D3, and since it HAS BEEN SUGGESTED that C/Ebpα CAN be considered a POTENTIAL tumor suppressor, these FINDINGS SUGGEST mechanisms whereby 1,25(Oh)2D3May act to inhibit Growth Of Breast cancer Cells.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 144), ('IMPORTANT_CONSIDERATION', 169), ('SUPERFICIAL_RELATIONSHIP', 178), ('SUPERFICIAL_RELATIONSHIP', 393), ('INCOMPLETE_EVIDENCE', 467), ('INCOMPLETE_EVIDENCE', 498), ('INCOMPLETE_EVIDENCE', 518), ('INCOMPLETE_EVIDENCE', 552), ('INCOMPLETE_EVIDENCE', 561)]	13	[('UBERON_0000310', 'breast', 59, 'breast'), ('PR_000003199', 'calcium/calmodulin-dependent protein kinase type II subunit alpha', 108, 'C/EBPα'), ('CHEBI_37958', 'dye', 235, '1,'), ('CHEBI_45409', 'ritonavir', 237, '25(OH)2D3in'), ('NCBITaxon_9606', 'Homo sapiens', 255, 'human'), ('UBERON_0000310', 'breast', 261, 'breast'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 284, 'EBPα'), ('CHEBI_27300', 'vitamin D', 330, 'vitamin D'), ('CHEBI_37983', 'sulfur-35 atom', 441, '1'), ('CHEBI_17996', 'chloride', 442, ','), ('CHEBI_73394', 'Ala-Ser', 443, '25(OH)2D3'), ('PR_000003199', 'calcium/calmodulin-dependent protein kinase type II subunit alpha', 491, 'C/EBPα'), ('CHEBI_37958', 'dye', 588, '1,'), ('CHEBI_83462', 'metolachlor OXA', 590, '25(OH)2D3may'), ('GO_0048468', 'cell development', 618, 'growth of ... cells'), ('UBERON_0000310', 'breast', 628, 'breast')]
S76-PMC3717170	PMC3717170	5/2013	S76-PMC3717170	['it WAS THOUGHT for decades that Human Milk was minimally sufficient in Vitamin D;17yet, PRELIMINARY results of the RECENTLY COMPLETED nichd Vitamin D supplementation trial during Lactation SHOW that when a mother is Vitamin D replete, with an Intake of 6400 iu Vitamin D3/day, Breast Milk is replete and a breastfeeding infant has excellent Vitamin D status without infant supplementation that is COMPARABLE to combined maternal and infant supplementation of 400 iu Vitamin D3/day.18the IMPLICATIONS of SAFELY achieving vitamin d SUFFICIENCY for both mother and breastfeeding infant solely through maternal supplementation is just BEGINNING TO BE UNDERSTOOD and will LIKELY CHALLENGE researchers for decades to come.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 189), ('INCOMPLETE_EVIDENCE', 397), ('IMPORTANT_CONSIDERATION', 487), ('IMPORTANT_CONSIDERATION', 503), ('IMPORTANT_CONSIDERATION', 530), ('INCOMPLETE_EVIDENCE', 631), ('PROBABLE_UNDERSTANDING', 667), ('DIFFICULT_TASK', 674)]	12	[('NCBITaxon_9606', 'Homo sapiens', 32, 'human'), ('UBERON_0001913', 'milk', 38, 'milk'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007595', 'lactation', 179, 'lactation'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007631', 'feeding behavior', 243, 'intake'), ('CHEBI_33279', 'vitamin D5', 261, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 261, 'vitamin D3'), ('UBERON_0000310', 'breast', 277, 'breast'), ('UBERON_0001913', 'milk', 284, 'milk'), ('CHEBI_27300', 'vitamin D', 341, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 466, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 466, 'vitamin D3')]
S318-PMC3728489	PMC3728489	7/2013	S318-PMC3728489	['the average level of Vitamin D in Breast Milk is TYPICALLY 25 iu per liter or less.']	[('PROBABLE_UNDERSTANDING', 49)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0000310', 'breast', 34, 'breast'), ('UBERON_0001913', 'milk', 41, 'milk')]
S1691-PMC4113768	PMC4113768	7/2014	S1691-PMC4113768	['background: MANY epidemiological STUDIES in RECENT years SUGGEST that Vitamin D is ASSOCIATED with a high RISK of osteoporotic fractures, malignancy of Breast, Colon, Prostate and many Respiratory diseases.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 83), ('IMPORTANT_CONSIDERATION', 106)]	5	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0000310', 'breast', 152, 'breast'), ('UBERON_0001155', 'colon', 160, 'colon'), ('UBERON_0002367', 'prostate gland', 167, 'prostate'), ('GO_0045333', 'cellular respiration', 185, 'respiratory'), ('UBERON_0001004', 'respiratory system', 185, 'respiratory')]
S84-PMC4169453	PMC4169453	9/2014	S84-PMC4169453	['for statistical purposes, Vitamin D intake from Breast Milk was ESTIMATED to be 20 iu/d (500 ml of Breast Milk) at baseline and 40 iu/d (1000 ml of Breast Milk) at follow-up visits.']	[('INCOMPLETE_EVIDENCE', 64)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 48, 'breast milk'), ('UBERON_0001348', 'brown adipose tissue', 99, 'breast milk'), ('UBERON_0000310', 'breast', 148, 'breast'), ('UBERON_0001913', 'milk', 155, 'milk')]
S66-PMC4329745	PMC4329745	10/2014	S66-PMC4329745	['insufficient Vitamin D MAY increase the RISK of Colon, Prostate, Breast and skin cancer as well as diabetes types i, multiple sclerosis and Arterial diseases.']	[('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 40)]	2	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('UBERON_0001155', 'colon', 48, 'colon'), ('UBERON_0002367', 'prostate gland', 55, 'prostate'), ('UBERON_0000310', 'breast', 65, 'breast'), ('UBERON_0001637', 'artery', 140, 'arterial')]
S1471-PMC4448820	PMC4448820	5/2015	S1471-PMC4448820	['BECAUSE Human Milk HAS BEEN SUGGESTED as a POTENTIALLY useful BIOMARKER of Vitamin A status of women and, by extrapolation, of their children and POTENTIALLY OTHER groups within the population (324), it is useful to explore the POTENTIAL IMPACT of inflammation on the use of Breast-Milk Vitamin A concentrations and interpretation.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 62), ('INCOMPLETE_EVIDENCE', 146), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('INCOMPLETE_EVIDENCE', 228), ('SUPERFICIAL_RELATIONSHIP', 238)]	8	[('NCBITaxon_9606', 'Homo sapiens', 8, 'human'), ('UBERON_0001913', 'milk', 14, 'milk'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin A'), ('UBERON_0000310', 'breast', 275, 'breast'), ('UBERON_0001913', 'milk', 282, 'milk'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin A')]
S92-PMC4452099	PMC4452099	6/2015	S92-PMC4452099	['AS the maternal Vitamin D fortification had EFFECT on babies´ Vitamin D levels via Breast feeding, Vitamin D intake during the first year of Life was LIKELY to HAVE BEEN lower than the maternal Intake.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 44), ('PROBABLE_UNDERSTANDING', 150), ('INCOMPLETE_EVIDENCE', 160)]	4	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('UBERON_0000310', 'breast', 83, 'breast'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('UBERON_0000104', 'life cycle', 141, 'life'), ('GO_0007631', 'feeding behavior', 194, 'intake')]
S8-PMC4908484	PMC4908484	6/2016	S8-PMC4908484	['ALTHOUGH in Human, most of the Vitamin D that ends up in the Blood is produced in the Kidneys, Vitamin D MAY BE synthesized in OTHER Tissues such as Endothelium, Placenta, Prostate, skin, Colon, Breast, and the Central Nervous System (Cns).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 105), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127)]	3	[('NCBITaxon_9606', 'Homo sapiens', 12, 'human'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('UBERON_0000178', 'blood', 61, 'blood'), ('UBERON_0002113', 'kidney', 86, 'kidneys'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0000479', 'tissue', 133, 'tissues'), ('UBERON_0001986', 'endothelium', 149, 'endothelium'), ('UBERON_0001987', 'placenta', 162, 'placenta'), ('UBERON_0002367', 'prostate gland', 172, 'prostate'), ('UBERON_0001155', 'colon', 188, 'colon'), ('UBERON_0000310', 'breast', 195, 'breast'), ('UBERON_0001017', 'central nervous system', 211, 'central nervous system'), ('UBERON_0001017', 'central nervous system', 235, 'CNS')]
S9-PMC4934634	PMC4934634	11/2015	S9-PMC4934634	['in the u.s. today, a DISPROPORTIONATE percentage of children with rickets are african american, who are characterized by low rates of Vitamin D synthesis, and exclusively Breast-Fed infants, who are characterized by low Vitamin D intakes.']	[('ANOMALY_CURIOUS_FINDING', 21), ('ANOMALY_CURIOUS_FINDING', 21)]	2	[('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007567', 'parturition', 171, 'breast'), ('UBERON_0000310', 'breast', 171, 'breast'), ('GO_0007631', 'feeding behavior', 178, 'fed'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D')]
S94-PMC4997421	PMC4997421	8/2016	S94-PMC4997421	['measurements of Vitamin A concentrations in Breast Milk, maternal Serum Vitamin A concentration, and maternal dietary intake SUGGEST that a maternal concentration of ≥1.05 µmol/l is NECESSARY in order to maintain a sufficient Vitamin A content in Breast Milk [26].']	[('INCOMPLETE_EVIDENCE', 125), ('IMPORTANT_CONSIDERATION', 182)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin A'), ('UBERON_0001348', 'brown adipose tissue', 44, 'breast milk'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 80, 'A'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin A'), ('UBERON_0000310', 'breast', 247, 'breast'), ('UBERON_0001913', 'milk', 254, 'milk')]
S6-PMC4997567	PMC4997567	8/2016	S6-PMC4997567	['the RISK FACTORS were low socioeconomic status, insufficient family income, poor housing conditions, lack of exposure to sunlight DUE TO cultural practices, sole Breast feeding, and inadequate supplementation of Vitamin D to the children and the Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('PROBLEM_COMPLICATION', 130)]	2	[('UBERON_0000310', 'breast', 162, 'breast'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'pregnant')]
S11-PMC4997567	PMC4997567	8/2016	S11-PMC4997567	['the risk factors contributing to Vitamin D deficiency rickets in the egyptian children include the low socioeconomic status, the limited exposure to sunlight due TO housing conditions and cultural practices, and the exclusive or prolonged Breast-feeding without Vitamin D supplements.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 162)]	1	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0000310', 'breast', 239, 'breast'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D')]
S91-PMC4997567	PMC4997567	8/2016	S91-PMC4997567	['(2008) [19], and bakeit and megeid (2012) [13], who REVEALED that most of the rickets children were Breast-Fed which may LEAD TO decreased Vitamin D 25-Hydroxy Vitamin D(25-Ohd) intake from OTHER sources and thereby causing rickets.']	[('INCOMPLETE_EVIDENCE', 52), ('PROBABLE_UNDERSTANDING', 121), ('SUPERFICIAL_RELATIONSHIP', 121), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 190)]	4	[('GO_0007567', 'parturition', 100, 'breast'), ('UBERON_0000310', 'breast', 100, 'breast'), ('GO_0007631', 'feeding behavior', 107, 'fed'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_43141', '3-hydroxypropoxy group', 149, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 170, '25-OHD')]
S93-PMC4997567	PMC4997567	8/2016	S93-PMC4997567	['(1992) [20] who OBSERVED that the Breast- Fed infant with insufficiency Intake of Vitamin D supplement are susceptible to nutritional rickets.']	[('INCOMPLETE_EVIDENCE', 16)]	1	[('UBERON_0000310', 'breast', 34, 'breast'), ('GO_0007631', 'feeding behavior', 42, 'fed'), ('GO_0007631', 'feeding behavior', 72, 'intake'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S94-PMC4997567	PMC4997567	8/2016	S94-PMC4997567	['hollis and wagner (2004) [21] NOTICED that ALTHOUGH Breast Milk is adequate for growth and bone mineralization in the first year of Life, it is lacking adequate concentration of Vitamin D. THEREFORE, Vitamin D supplementation MUST BE NECESSARY for Breast-Fed infants.']	[('ANOMALY_CURIOUS_FINDING', 30), ('ANOMALY_CURIOUS_FINDING', 43), ('PROBABLE_UNDERSTANDING', 189), ('IMPORTANT_CONSIDERATION', 226), ('IMPORTANT_CONSIDERATION', 234)]	5	[('UBERON_0000310', 'breast', 52, 'breast'), ('UBERON_0001913', 'milk', 59, 'milk'), ('UBERON_0000104', 'life cycle', 132, 'life'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0000310', 'breast', 248, 'breast'), ('GO_0007631', 'feeding behavior', 255, 'fed')]
S103-PMC4997567	PMC4997567	8/2016	S103-PMC4997567	['several RISK FACTORS had IMPORTANT CONTRIBUTIONS, including low socio-economic status represented by low family income, low standard of education, poor housing conditions, lack of exposure to sunlight, nutritional status of mother, and prolonged Breast-Feeding without Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 8), ('IMPORTANT_CONSIDERATION', 25), ('SUPERFICIAL_RELATIONSHIP', 35)]	3	[('GO_0007567', 'parturition', 246, 'breast-'), ('UBERON_0000310', 'breast', 246, 'breast'), ('GO_0007631', 'feeding behavior', 253, 'feeding'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
S69-PMC5014971	PMC5014971	8/2016	S69-PMC5014971	['respondents were CONCERNED about Vitamin D deficiency and osteoporosis (91.1%) and bone fractures (88.1%), but less CONCERNED about other POSSIBLE sequelae of Vitamin D deficiency such as a weakened Immune System (32.7%), Colon cancer (27.7%), Cardiovascular disease (23.8%), impaired glucose Metabolism (22.8%), vulnerability to preeclampsia (22.8%), increased risk of small-for-Gestational-age infant (21.8%), vulnerability to Preterm Labor (19.8%), Breast cancer (14.9%), hypertension (12.9%), and infertility (10.9%).']	[('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 116), ('INCOMPLETE_EVIDENCE', 138)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('UBERON_0002405', 'immune system', 199, 'immune system'), ('UBERON_0001155', 'colon', 222, 'colon'), ('UBERON_0004535', 'cardiovascular system', 244, 'cardiovascular'), ('GO_0008152', 'metabolic process', 293, 'metabolism'), ('GO_0007565', 'female pregnancy', 380, 'gestational'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 429, 'preterm labor'), ('UBERON_0000310', 'breast', 452, 'breast')]
S80-PMC5030591	PMC5030591	9/2016	S80-PMC5030591	"[""caption (table-wrap): table 4\n\nthemes and elements relating to specific Conception and Pregnancy information for women with rheumatoid arthritis and their familiessaying : information that should be discussed by health professionals doing : actions that SHOULD BE undertaken by health professionals review of current Medications in relation to safety during Conception and Pregnancy (100%) prior to Conception and Pregnancy, review current Medication(s) and discuss:\nmedications vary with respect to their SAFETY during Pregnancy and RISKS related to Fertility, Ovulation, Conception and Miscarriage\nSOME Medicines used in ra care MAY have EFFECTS on Fertility, Conception and Pregnancy process, for example, regular Nsaids MAY impair fertility and ASSOCIATED RISKS with fetus\nit is IMPORTANT to time Conceptionprovide GUIDANCE as to WHERE to obtain reliable information about SAFETY of Medicines in Pregnancywhere current Medication(s) is (are) contraindicated for Conception/Pregnancy the following SHOULD BE discussed with the patient:\nthere are SAFE Medication options pre, during (including Delivery) and Postpregnancy (including Breast feeding)\ntiming is IMPORTANT in RELATION to ceasing or switching of current Medications and allowing for washout periods prior to Conception\nthere is a need for close supervision/monitoring by a rheumatologist when discontinuing current Medications prior to Pregnancy, including CONSIDERING POTENTIAL NEED for disease stabilisation on new treatment prior to Conception and Pregnancydiscuss IMPACT of ra pathology on Pregnancy and Pregnancy on ra (100%) there are DIFFERENT SCENARIOS regarding ra disease activity during Pregnancy (eg, POSSIBLE remission/low disease activity)discuss: ra-related pain management options during Pregnancyconception MAY take longer compared with women who do not have rathere is a need to balance disease Control with maternal and fetal health and safetyra MAY AFFECT Pregnancy and Pregnancy MAY AFFECT ra, and there are POSSIBLE adverse outcomes where risks are identified (eg, Prematurity)there are significant risks ASSOCIATED with active or uncontrolled ra for the mother and baby, ESPECIALLY irreversible Joint damage and functional impairmentpregnancy MAY change a patient’s health outlook in the futurethe size of the baby MAY BE smaller than women without ra and MAY also be Delivered pre-term discuss IMPORTANT elements of Preconception care RELEVANT to patient (97.1%) it is IMPORTANT to achieve optimal disease control prior to considering Pregnancy—Planning Conception is preferable after patients achieve and maintain low disease activityencourage and facilitate early discussions with all health practitioners involved in care about family planning to allow for adequate preparationthere is a CRITICAL need for a planned Pregnancy RATHER than an unplanned Pregnancyreview Prenatal nutrition, including need for dietary/vitamin supplements (ie, Folic Acid, calcium, Vitamin D, Iodine, iron)history of previous Attempts To Conceive/Pregnancies or Pregnancy-related complications (eg, Miscarriage) and other relevant patient history (such as smoking/Illicit Drug use history, family history of hereditary issues) MAY AFFECT Pregnancyundertake RELEVANT health checks such as immunisation status (eg, rubella, varicella, pertussis), Sexually Transmitted disease screening, pap test, screening for other Autoimmune disorders that MAY IMPACT on Pregnancyweight management and appropriate exercise are very IMPORTANTCONSIDER the NEED for review of diabetes or impaired Glucose tolerance if RISK factors are present (eg, on Steroid medication or overweight/obese)it is IMPORTANT to manage comorbid conditions, such as diabetes and hypertensionsome women MAY NEED to avoid Conception during a flarera disease activity MAY or MAY not improve with Pregnancy and there is a LIKELIHOOD of Postpartum flares importance of maintaining optimistic outlook and providing positive messages (97.1%) Pregnancy and Breast feeding success rates are near normal in women with mild to moderate ra nowadays (where appropriate for the patient's clinical status)ra is not a BARRIER to Pregnancystrategies to address anxiety, stress and depression (if relevant) are IMPORTANT, such as mindfulness meditation need for close monitoring of a patient prior to and during Pregnancy, where indicated (94.1%) it is IMPORTANCE to have a healthcare team with expertise in Autoimmune disorders for SOME women with radetermine THE NEED for high-level obstetric care during a Pregnancy (where indicated), including the need for Anaesthetic inputsome women REQUIRE closer monitoring of their Pregnancy and this is USUALLY proportional to disease activity, comorbidities and maternal historyassess the REQUIREMENTS for any extra treatment or monitoring prior to, or during, Pregnancyit is IMPORTANT to develop a Pregnancy plan, which includes different options for management of ra and support for different scenariosvaginal Delivery MAY NOT always BE POSSIBLE, depending on condition of the patient's Hips.""]"	[('FUTURE_WORK', 254), ('IMPORTANT_CONSIDERATION', 506), ('IMPORTANT_CONSIDERATION', 534), ('INCOMPLETE_EVIDENCE', 600), ('INCOMPLETE_EVIDENCE', 631), ('SUPERFICIAL_RELATIONSHIP', 640), ('INCOMPLETE_EVIDENCE', 724), ('SUPERFICIAL_RELATIONSHIP', 749), ('IMPORTANT_CONSIDERATION', 760), ('IMPORTANT_CONSIDERATION', 783), ('FUTURE_WORK', 819), ('EXPLICIT_QUESTION', 834), ('IMPORTANT_CONSIDERATION', 877), ('FUTURE_WORK', 1001), ('IMPORTANT_CONSIDERATION', 1049), ('IMPORTANT_CONSIDERATION', 1161), ('SUPERFICIAL_RELATIONSHIP', 1174), ('FUTURE_WORK', 1421), ('IMPORTANT_CONSIDERATION', 1421), ('INCOMPLETE_EVIDENCE', 1433), ('SUPERFICIAL_RELATIONSHIP', 1532), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1605), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('INCOMPLETE_EVIDENCE', 1677), ('INCOMPLETE_EVIDENCE', 1788), ('INCOMPLETE_EVIDENCE', 1929), ('SUPERFICIAL_RELATIONSHIP', 1933), ('INCOMPLETE_EVIDENCE', 1964), ('SUPERFICIAL_RELATIONSHIP', 1968), ('INCOMPLETE_EVIDENCE', 1993), ('SUPERFICIAL_RELATIONSHIP', 2091), ('IMPORTANT_CONSIDERATION', 2158), ('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2302), ('INCOMPLETE_EVIDENCE', 2343), ('IMPORTANT_CONSIDERATION', 2382), ('SUPERFICIAL_RELATIONSHIP', 2423), ('IMPORTANT_CONSIDERATION', 2457), ('IMPORTANT_CONSIDERATION', 2779), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2817), ('INCOMPLETE_EVIDENCE', 3196), ('SUPERFICIAL_RELATIONSHIP', 3200), ('IMPORTANT_CONSIDERATION', 3226), ('INCOMPLETE_EVIDENCE', 3410), ('SUPERFICIAL_RELATIONSHIP', 3414), ('IMPORTANT_CONSIDERATION', 3485), ('INCOMPLETE_EVIDENCE', 3507), ('SUPERFICIAL_RELATIONSHIP', 3568), ('IMPORTANT_CONSIDERATION', 3646), ('INCOMPLETE_EVIDENCE', 3731), ('FUTURE_WORK', 3735), ('IMPORTANT_CONSIDERATION', 3735), ('INCOMPLETE_EVIDENCE', 3794), ('INCOMPLETE_EVIDENCE', 3801), ('PROBABLE_UNDERSTANDING', 3847), ('DIFFICULT_TASK', 4131), ('IMPORTANT_CONSIDERATION', 4222), ('IMPORTANT_CONSIDERATION', 4364), ('INCOMPLETE_EVIDENCE', 4444), ('INCOMPLETE_EVIDENCE', 4472), ('IMPORTANT_CONSIDERATION', 4600), ('INCOMPLETE_EVIDENCE', 4657), ('IMPORTANT_CONSIDERATION', 4744), ('IMPORTANT_CONSIDERATION', 4831), ('INCOMPLETE_EVIDENCE', 4976), ('DIFFICULT_TASK', 4980)]	66	[('GO_0007631', 'feeding behavior', 72, 'conception ...'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_25441', 'mycothiols', 317, 'medications'), ('GO_0007620', 'copulation', 358, 'conception'), ('GO_0007565', 'female pregnancy', 373, 'pregnancy'), ('GO_0007620', 'copulation', 399, 'conception'), ('GO_0007565', 'female pregnancy', 414, 'pregnancy'), ('CHEBI_60211', 'compound Z', 440, 'medication'), ('GO_0007565', 'female pregnancy', 520, 'pregnancy'), ('GO_0009566', 'fertilization', 551, 'fertility'), ('GO_0030728', 'ovulation', 562, 'ovulation'), ('GO_0007620', 'copulation', 573, 'conception'), ('GO_0046660', 'female sex differentiation', 588, 'miscarriage'), ('CHEBI_25179', 'melanins', 605, 'medicines'), ('GO_0009566', 'fertilization', 651, 'fertility'), ('GO_0007620', 'copulation', 662, 'conception'), ('GO_0007565', 'female pregnancy', 677, 'pregnancy'), ('CHEBI_16039', 'ITP', 717, 'NSAIDs'), ('GO_0070268', 'cornification', 801, 'conceptionProvide'), ('CHEBI_25179', 'melanins', 887, 'medicines'), ('GO_0000712', 'resolution of meiotic recombination intermediates', 900, 'pregnancyWhere'), ('CHEBI_60211', 'compound Z', 923, 'medication'), ('GO_0007620', 'copulation', 966, 'conception'), ('GO_0007565', 'female pregnancy', 977, 'pregnancy'), ('CHEBI_60211', 'compound Z', 1054, 'medication'), ('GO_0007567', 'parturition', 1096, 'delivery'), ('GO_0007565', 'female pregnancy', 1110, 'postpregnancy'), ('UBERON_0000310', 'breast', 1135, 'breast'), ('CHEBI_25441', 'mycothiols', 1218, 'medications'), ('GO_0007620', 'copulation', 1272, 'conception'), ('CHEBI_25441', 'mycothiols', 1379, 'medications'), ('GO_0007565', 'female pregnancy', 1400, 'pregnancy'), ('GO_0007620', 'copulation', 1500, 'conception'), ('GO_0006915', 'apoptotic process', 1515, 'pregnancyDiscuss'), ('GO_0007565', 'female pregnancy', 1558, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1572, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1662, 'pregnancy'), ('GO_0007602', 'phototransduction', 1768, 'pregnancyConception'), ('GO_0065007', 'biological regulation', 1877, 'control'), ('GO_0007565', 'female pregnancy', 1940, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1954, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2051, 'prematurity'), ('UBERON_0004905', 'articulation', 2182, 'joint'), ('GO_0007567', 'parturition', 2355, 'delivered'), ('GO_0007565', 'female pregnancy', 2404, 'preconception'), ('GO_0007565', 'female pregnancy', 2523, 'pregnancy'), ('GO_0006260', 'DNA replication', 2533, 'planning'), ('GO_0007620', 'copulation', 2542, 'conception'), ('GO_0007565', 'female pregnancy', 2807, 'pregnancy'), ('GO_0006412', 'translation', 2842, 'pregnancyReview'), ('GO_0007565', 'female pregnancy', 2858, 'prenatal'), ('CHEBI_30751', 'formic acid', 2930, 'folic acid'), ('CHEBI_27300', 'vitamin D', 2951, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 2962, 'iodine'), ('GO_0000380', 'alternative mRNA splicing, via spliceosome', 2995, 'attempts to conceive'), ('GO_0007565', 'female pregnancy', 3016, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3031, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3068, 'miscarriage'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 3133, 'illicit drug'), ('GO_0051610', 'serotonin uptake', 3207, 'pregnancyUndertake'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 3314, 'sexually transmitted'), ('UBERON_0001442', 'skeleton of manus', 3384, 'autoimmune'), ('GO_0006412', 'translation', 3424, 'pregnancyWeight'), ('CHEBI_17234', 'glucose', 3547, 'glucose'), ('CHEBI_35341', 'steroid', 3601, 'steroid'), ('GO_0007620', 'copulation', 3749, 'conception'), ('GO_0007565', 'female pregnancy', 3822, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3861, 'postpartum'), ('GO_0007565', 'female pregnancy', 3964, 'Pregnancy'), ('UBERON_0000310', 'breast', 3978, 'breast'), ('GO_0006915', 'apoptotic process', 4142, 'pregnancyStrategies'), ('GO_0007565', 'female pregnancy', 4323, 'pregnancy'), ('UBERON_0001442', 'skeleton of manus', 4419, 'autoimmune'), ('GO_0007565', 'female pregnancy', 4520, 'pregnancy'), ('CHEBI_38867', 'anaesthetic', 4572, 'anaesthetic'), ('GO_0007565', 'female pregnancy', 4635, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4816, 'pregnancyIt'), ('GO_0007565', 'female pregnancy', 4854, 'pregnancy'), ('GO_0007567', 'parturition', 4967, 'delivery'), ('UBERON_0000988', 'pons', 5044, 'hips')]
S70-PMC5054480	PMC5054480	9/2016	S70-PMC5054480	['caption (table-wrap): table 2\n\nchanges in Calcium Homeostasis during Pregnancy and Lactationmeasured levelspregnant womanplacentafetuslactating womanserum Catotal Ca ↓Ionized Ca↔Intestinal Absorption twofold ↑active transfer DEPENDENT on Pthrp+ passive transferhigher than maternal levels; Regulated by fetal pthrpionized Ca slightly ↑Bone Resorption ↑Urinary Ca↑unknown↔pth↓↔no transferlowlowpthrpprogressively ↑ secretion by Decidua and Breastsno transfer; Placental and amniotic secretionhigher than in mothersecretion by the Umbilical Cord and Fetal Parathyroid Glands as early as 10 weeks↑↑: secretion by breasts25‐Vitamin D↔transfer; Placental hydroxylationrenal hydroxylation↔1,25‐dihydroxyvitamin dprogressive ↑ by 100%; Calbindin‐D9K ↑no transferlow↔1 α ‐hydroxylase activity↑stimulated by Estradiol, prolactin, Placental Lactogen, pthrppresentpresent in the Kidney↔Calcitonin↑ by 20%secretion by Thyroid and breastsno transfer; Placental secretion↑ in the first 6 weeks\nca, calcium level; Pthrp, Parathyroid Hormone‐Related Protein; Calbindin‐D9K, Vitamin D‐dependent calcium‐binding protein.']	[('SUPERFICIAL_RELATIONSHIP', 225)]	1	[('GO_0055073', 'cadmium ion homeostasis', 42, 'calcium homeostasis'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('GO_0001764', 'neuron migration', 83, 'lactationMeasured'), ('CHEBI_17793', 'calycosin', 155, 'CaTotal'), ('CHEBI_32588', 'potassium chloride', 163, 'Ca'), ('CHEBI_24870', 'ion', 166, '↓'), ('CHEBI_5893', 'indapamide', 167, 'Ionized'), ('GO_0070481', 'nuclear-transcribed mRNA catabolic process, non-stop decay', 167, 'Ionized'), ('CHEBI_32588', 'potassium chloride', 175, 'Ca'), ('GO_0050892', 'intestinal absorption', 178, 'Intestinal absorption'), ('UBERON_0000160', 'intestine', 178, 'Intestinal'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 238, 'PTHrP'), ('GO_0065007', 'biological regulation', 290, 'regulated'), ('CHEBI_32588', 'potassium chloride', 322, 'Ca'), ('GO_0097578', 'sequestering of copper ion', 335, 'Bone resorption'), ('UBERON_0001088', 'urine', 352, 'Urinary'), ('CHEBI_32588', 'potassium chloride', 360, 'Ca'), ('UBERON_0002450', 'decidua', 427, 'decidua'), ('UBERON_0000310', 'breast', 439, 'breastsNo'), ('UBERON_0001987', 'placenta', 459, 'placental'), ('UBERON_0002331', 'umbilical cord', 529, 'umbilical cord'), ('UBERON_0000922', 'embryo', 548, 'fetal'), ('UBERON_0001132', 'parathyroid gland', 554, 'parathyroid glands'), ('CHEBI_27300', 'vitamin D', 620, 'vitamin D'), ('UBERON_0001987', 'placenta', 640, 'placental'), ('PR_000004968', 'calretinin', 729, 'calbindin'), ('PR_000002325', 'dynein light chain 1, cytoplasmic', 739, 'D9k'), ('CHEBI_23965', 'estradiol', 799, 'estradiol'), ('CHEBI_81588', 'Placental lactogen', 821, 'placental lactogen'), ('PR_000012764', 'piwi-like protein 3', 821, 'placental lactogen'), ('UBERON_0001987', 'placenta', 821, 'placental'), ('UBERON_0002113', 'kidney', 868, 'kidney'), ('CHEBI_17793', 'calycosin', 875, 'Calcitonin'), ('UBERON_0002046', 'thyroid gland', 906, 'thyroid'), ('UBERON_0001987', 'placenta', 938, 'placental'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 999, 'PTHrP'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 1006, 'parathyroid hormone'), ('UBERON_0001132', 'parathyroid gland', 1006, 'parathyroid'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 1026, 'related protein'), ('PR_000004968', 'calretinin', 1043, 'calbindin'), ('PR_000002325', 'dynein light chain 1, cytoplasmic', 1053, 'D9k'), ('CHEBI_27300', 'vitamin D', 1058, 'vitamin D')]
S4-PMC5129897	PMC5129897	10/2016	S4-PMC5129897	['we used 25(Oh)D concentration–health outcome RELATIONS for Breast cancer and Cardiovascular disease and results of clinical trials with Vitamin D for Respiratory infections and Musculoskeletal disorders to ESTIMATE the reductions in disease BURDEN for increased 25(Oh)D concentrations.']	[('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 206), ('IMPORTANT_CONSIDERATION', 241)]	3	[('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 14, 'D'), ('UBERON_0000310', 'breast', 59, 'breast'), ('UBERON_0004535', 'cardiovascular system', 77, 'cardiovascular'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 150, 'respiratory'), ('UBERON_0002204', 'musculoskeletal system', 177, 'musculoskeletal'), ('CHEBI_71657', 'versiconol acetate', 262, '25(OH)D')]
S63-PMC5322422	PMC5322422	2/2017	S63-PMC5322422	['this form nearly always occurs in exclusively Breast-Fed infants and is OFTEN ASSOCIATED with undiagnosed Hepatobiliary dysfunction impairing absorption of Vitamin K [1].']	[('PROBABLE_UNDERSTANDING', 72), ('SUPERFICIAL_RELATIONSHIP', 78)]	2	[('GO_0007567', 'parturition', 46, 'breast'), ('UBERON_0000310', 'breast', 46, 'breast'), ('GO_0007631', 'feeding behavior', 53, 'fed'), ('UBERON_0002423', 'hepatobiliary system', 106, 'hepatobiliary'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin K')]
S136-PMC5368580	PMC5368580	4/2017	S136-PMC5368580	['EVEN THOUGH the increase in all 4 Vitamins was significant and substantial from both doses, ONLY 0.05–0.35% of Thiamin, 0.54–0.6% of riboflavin, 1.0–1.14% of Vitamin B-6, and 4.85–6.17% of Vitamin A in the supplements were Secreted into the Breast Milk and subsequently available to the infant ( table 3 ).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 92)]	2	[('CHEBI_33277', 'gamma-tocotrienol', 34, 'vitamins'), ('CHEBI_26948', 'vitamin B1', 111, 'thiamin'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A'), ('GO_0046903', 'secretion', 223, 'secreted'), ('UBERON_0000310', 'breast', 241, 'breast'), ('UBERON_0001913', 'milk', 248, 'milk')]
S167-PMC5368580	PMC5368580	4/2017	S167-PMC5368580	['(29) FOUND higher amounts of Vitamin B-12 in Hindmilk than in Foremilk, trugo and sardinha (34) FOUND no differences in Vitamin B-12 concentration within Feedings, between Breasts, or over the day.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 96)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 29, 'vitamin B-12'), ('UBERON_0001466', 'pedal digit', 45, 'hindmilk'), ('UBERON_0002386', 'forelimb zeugopod', 62, 'foremilk'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin B'), ('GO_0007631', 'feeding behavior', 154, 'feedings'), ('UBERON_0000310', 'breast', 172, 'breasts')]
S31-PMC5405075	PMC5405075	4/2017	S31-PMC5405075	['the most cited adverse outcome of maternal Vitamin D deficiency is neonatal rickets, WHILE mild hypovitaminosis D COULD BE more pronounced in exclusively Breast-Fed infants, on the BASIS that Breast Milk constitutes a POOR source of Vitamin D compared with formulas (34–36).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('ANOMALY_CURIOUS_FINDING', 85), ('INCOMPLETE_EVIDENCE', 114), ('PROBABLE_UNDERSTANDING', 181), ('IMPORTANT_CONSIDERATION', 218)]	5	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 112, 'D'), ('GO_0007567', 'parturition', 154, 'breast'), ('UBERON_0000310', 'breast', 154, 'breast'), ('GO_0007631', 'feeding behavior', 161, 'fed'), ('UBERON_0001348', 'brown adipose tissue', 192, 'breast milk'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D')]
S31-PMC5489519	PMC5489519	6/2017	S31-PMC5489519	['results\n\nVitamin D deficiency in mothers increases Trail Expression in Breast Milk\nphysiologic levels of Vitamin D HAS BEEN IMPLICATED as an IMPORTANT stimulant for Innate Immunity and Bone Remodeling.']	[('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 124), ('IMPORTANT_CONSIDERATION', 141)]	3	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 51, 'TRAIL'), ('GO_0010467', 'gene expression', 57, 'expression'), ('UBERON_0000310', 'breast', 71, 'breast'), ('UBERON_0001913', 'milk', 78, 'milk'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0045087', 'innate immune response', 165, 'innate immunity'), ('GO_0046849', 'bone remodeling', 185, 'bone remodeling')]
S46-PMC5489519	PMC5489519	6/2017	S46-PMC5489519	['these results SUGGEST that Vitamin D status in mothers Modulate Trail Expression levels in Human Breast Milk.']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0065007', 'biological regulation', 55, 'modulate'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 64, 'TRAIL'), ('GO_0010467', 'gene expression', 70, 'expression'), ('NCBITaxon_9606', 'Homo sapiens', 91, 'human'), ('UBERON_0000310', 'breast', 97, 'breast'), ('UBERON_0001913', 'milk', 104, 'milk')]
S62-PMC5489519	PMC5489519	6/2017	S62-PMC5489519	['effect of Vitamin D on Trail Expression in Human Breast Epithelial Cells\nsince the Expression of Trail is elevated in Vitamin D deficient mothers’ Breast Milk, we next examined the direct EFFECT of Vitamin D on normal Human Breast Epithelial Cells to analyze the Trail Expression.']	[('SUPERFICIAL_RELATIONSHIP', 188)]	1	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 23, 'TRAIL'), ('GO_0010467', 'gene expression', 29, 'expression'), ('NCBITaxon_9606', 'Homo sapiens', 43, 'human'), ('CL_0002327', 'mammary gland epithelial cell', 49, 'breast epithelial cells'), ('UBERON_0008367', 'breast epithelium', 49, 'breast epithelial'), ('GO_0010467', 'gene expression', 83, 'expression'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 97, 'TRAIL'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('UBERON_0000310', 'breast', 147, 'breast'), ('UBERON_0001913', 'milk', 154, 'milk'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 218, 'human'), ('CL_0002327', 'mammary gland epithelial cell', 224, 'breast epithelial cells'), ('UBERON_0008367', 'breast epithelium', 224, 'breast epithelial'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 263, 'TRAIL'), ('GO_0010467', 'gene expression', 269, 'expression')]
S89-PMC5489519	PMC5489519	6/2017	S89-PMC5489519	['Vitamin D supplementation of mothers results in Vitamin D sufficiency in Breast-Fed infants13, THUS POTENTIALLY Modulating the Immune signature of maternal Breast Milk to her recipient infant.']	[('PROBABLE_UNDERSTANDING', 95), ('INCOMPLETE_EVIDENCE', 100)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0000310', 'breast', 73, 'breast'), ('GO_0007631', 'feeding behavior', 80, 'fed'), ('GO_0065007', 'biological regulation', 112, 'modulating'), ('UBERON_0002405', 'immune system', 127, 'immune'), ('UBERON_0001348', 'brown adipose tissue', 156, 'breast milk')]
S12-PMC5679631	PMC5679631	11/2017	S12-PMC5679631	['difficile were ASSOCIATED with Vitamin D supplementation of Breast Fed infants whose mothers were more LIKELY to adhere to an alternative lifestyle in terms of, e .']	[('SUPERFICIAL_RELATIONSHIP', 15), ('PROBABLE_UNDERSTANDING', 103)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('UBERON_0000310', 'breast', 60, 'breast'), ('GO_0007631', 'feeding behavior', 67, 'fed')]
S78-PMC5679631	PMC5679631	11/2017	S78-PMC5679631	['the analyses concerning Vitamin D supplementation of the Breast Fed infant included 616 Individuals after omitting infants receiving formula (n = 208), both Breast Milk and formula (n = 87) and lack OF information regarding Feeding (n = 2).']	[('ANOMALY_CURIOUS_FINDING', 199)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0000310', 'breast', 57, 'breast'), ('GO_0007631', 'feeding behavior', 64, 'fed'), ('NCBITaxon_1', 'root', 88, 'individuals'), ('UBERON_0000310', 'breast', 157, 'breast'), ('UBERON_0001913', 'milk', 164, 'milk'), ('GO_0007631', 'feeding behavior', 224, 'feeding')]
S84-PMC5679631	PMC5679631	11/2017	S84-PMC5679631	['the characteristics of the Breast Fed children were fairly SIMILAR between the children receiving Vitamin D supplementation and those who did not, except that mothers who were recruited in the conventional recruitment group were more LIKELY to give their child Vitamin D supplementation than those in the alternative recruitment group.']	[('SUPERFICIAL_RELATIONSHIP', 59), ('PROBABLE_UNDERSTANDING', 234)]	2	[('GO_0007567', 'parturition', 27, 'breast fed'), ('UBERON_0000310', 'breast', 27, 'breast'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D')]
S105-PMC5679631	PMC5679631	11/2017	S105-PMC5679631	['600 (reference)0 (reference)quintile 2680.01 (-0.21, 0.24)0.01 (-0.21, 0.22)quintile 349-0.11 (-0.35, 0.14)-0.18 (-0.41, 0.06)quintile 4510.02 (-0.22, 0.26)0.04 (-0.20, 0.28)quintile 558-0.06 (-0.30, 0.17)0.08 (-0.17, 0.33)p for linear trendp = 0.459\n&number of children colonized;\n#adjusted for: place and mode of Delivery, number of siblings, recruitment group, total bacterial counts, sex, vaginitis during the last month of Pregnancy, mode of infant nutrition and season of Blood sampling; quintile 5 is the highest quintile;\n* remained statistically significant after correction with fdr (q < 0.05)\n\nVitamin D supplementation of the infant\nthere was no influence of Vitamin D supplementation of the infant during the first month of Life on the prevalence of any of the bacterial species or groups (data not shown).table 5shows the ASSOCIATION between Vitamin D supplementation of the infant in the first month of Life and the log10cfus of the different bacteria in children colonized with the respective bacterial group or species (for a visualisation of the data in univariable boxplots see alsos3 fig).10.1371/journal.pone.0188011.t005\n\ncaption (table-wrap): table 5\nassociation between Vitamin D supplementation of the infant and log10colony forming units/g Feces of bacterial species or groups in Breast Fed infants (n = 616) colonized with the respective bacteria.Vitamin D supplement use of Breast feeding infantsvitamin D supplementationbacteria&nunadjusted b (95% ci)#adjusted b (95% ci)no use bifidobacterium spp.']	[('SUPERFICIAL_RELATIONSHIP', 836)]	1	[('GO_0007567', 'parturition', 315, 'delivery'), ('GO_0007565', 'female pregnancy', 428, 'pregnancy'), ('UBERON_0000178', 'blood', 478, 'blood'), ('CHEBI_28384', 'vitamin K', 605, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 671, 'vitamin D'), ('UBERON_0000104', 'life cycle', 737, 'life'), ('CHEBI_27300', 'vitamin D', 856, 'vitamin D'), ('UBERON_0000104', 'life cycle', 918, 'life'), ('CHEBI_27300', 'vitamin D', 1194, 'vitamin D'), ('UBERON_0001988', 'feces', 1266, 'feces'), ('GO_0007567', 'parturition', 1306, 'breast'), ('UBERON_0000310', 'breast', 1306, 'breast'), ('GO_0007631', 'feeding behavior', 1313, 'fed'), ('CHEBI_28384', 'vitamin K', 1374, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1374, 'Vitamin'), ('UBERON_0000310', 'breast', 1402, 'Breast'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1432, 'D')]
S151-PMC5679631	PMC5679631	11/2017	S151-PMC5679631	['the number of infants not administered Vitamin D supplementation was low because it is standard PRACTICE to supplement Breast Fed children with Vitamin D, and the lower prevalence of colonization with these bacteria also CONTRIBUTED to this LIMITATION.']	[('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 221), ('INCOMPLETE_EVIDENCE', 241)]	3	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007567', 'parturition', 119, 'breast'), ('UBERON_0000310', 'breast', 119, 'breast'), ('GO_0007631', 'feeding behavior', 126, 'fed'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S13-PMC5707701	PMC5707701	11/2017	S13-PMC5707701	['since infants are Born with very low reserves of Vitamin A in the Liver REGARDLESS of the mother’s nutritional status [3], they rely entirely on Breast Milk to support growth and build up Liver storage.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 72)]	1	[('GO_0007567', 'parturition', 18, 'born'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin A'), ('UBERON_0002107', 'liver', 66, 'liver'), ('UBERON_0000310', 'breast', 145, 'breast'), ('UBERON_0001913', 'milk', 152, 'milk'), ('UBERON_0002107', 'liver', 188, 'liver')]
S130-PMC5707701	PMC5707701	11/2017	S130-PMC5707701	['the results from a 24-h Food Intake Recall SHOWED that dietary Vitamin A and total Carotenoids were not associated with all of the Carotenoids in Breast Milk when adjusted with different Cities and Lactation period ( p> 0.05) (table 5).']	[('INCOMPLETE_EVIDENCE', 43)]	1	[('CHEBI_33290', 'food', 24, 'food'), ('GO_0007631', 'feeding behavior', 24, 'food intake'), ('GO_0060033', 'anatomical structure regression', 36, 'recall'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin A'), ('CHEBI_50815', 'norgestimate', 83, 'carotenoids'), ('CHEBI_50815', 'norgestimate', 131, 'carotenoids'), ('UBERON_0000310', 'breast', 146, 'breast'), ('UBERON_0001913', 'milk', 153, 'milk'), ('UBERON_0000978', 'leg', 187, 'cities'), ('GO_0007595', 'lactation', 198, 'lactation')]
S158-PMC5941617	PMC5941617	5/2018	S158-PMC5941617	['in the present consensus we RECOMMEND a total daily Vitamin D intake of 200–400\xa0iu (including the amount administered through parenteral nutrition, fortified Breast Milk, and preterm formula) for preterm infants with a Birth weight\u2009<\u20091500\xa0g. Vitamin D supplementation at 400–800\xa0iu/day is RECOMMENDED for vlbw infants when they reach a weight\u2009≥\u20091500\xa0g and full enteral nutrition, and for preterm infants with a Birth weight\u2009≥\u20091500\xa0g. after a post-Conceptional age of 40\xa0weeks, RECOMMENDATIONS for Vitamin D supplementation are equal to those for healthy term infants.']	[('FUTURE_WORK', 28), ('FUTURE_WORK', 289), ('FUTURE_WORK', 477)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0000310', 'breast', 158, 'breast'), ('UBERON_0001913', 'milk', 165, 'milk'), ('GO_0007567', 'parturition', 219, 'birth'), ('CHEBI_28384', 'vitamin K', 242, 'Vitamin D'), ('GO_0007567', 'parturition', 411, 'birth'), ('GO_0007620', 'copulation', 447, 'conceptional'), ('CHEBI_27300', 'vitamin D', 497, 'vitamin D')]
S629-PMC5941617	PMC5941617	5/2018	S629-PMC5941617	['preterm infants\n\nwe SUGGEST for vlbw infants a Vitamin D intake of 200–400\xa0iu/day (including the amount administered through parenteral nutrition, fortified Breast milk, or preterm infant formula).']	[('INCOMPLETE_EVIDENCE', 20)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0000310', 'breast', 157, 'breast')]
S148-PMC5995352	PMC5995352	6/2018	S148-PMC5995352	['IN KEEPING WITH our results, longitudinal growth trajectories at age seven months were SIMILAR in Breast vs. formula Fed infants in an american cohort studying maternal Vitamin D supplementation during Lactation [37].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 87)]	2	[('UBERON_0000310', 'breast', 98, 'breast'), ('GO_0007631', 'feeding behavior', 117, 'fed'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007595', 'lactation', 202, 'lactation')]
